Cryo-Cell International, Inc. (FRA:ZCY)
Germany · Delayed Price · Currency is EUR | Market Cap | 20.48M -47.2% |
| Revenue (ttm) | 26.47M -2.6% |
| Net Income | -2.26M |
| EPS | -0.28 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 27.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 3.120 |
| Previous Close | 3.100 |
| Day's Range | 3.120 - 3.120 |
| 52-Week Range | 2.320 - 4.600 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 10, 2026 |
About Cryo-Cell International
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold st... [Read more]
News
Cryo-Cell says NYSE American accepts compliance plan
Cryo-Cell (CCEL) announced that the NYSE American has accepted the company’s previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, the c...
Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced t...
Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank, has been granted renewed Foundation for the Accredit...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced ...
Cryo-Cell International Quarterly report: Q1 2026
Cryo-Cell International has published its Q1 2026 quarterly earnings report on April 14, 2026.
Cryo-Cell International Earnings release: Q1 2026
Cryo-Cell International released its Q1 2026 earnings on April 14, 2026, summarizing the period's financial results.
Cryo-Cell Receives NYSE American Continued Listing Notice
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced t...
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced r...
Cryo-Cell International Annual report: Q4 2025
Cryo-Cell International has published its Q4 2025 annual report on February 27, 2026.
Cryo-Cell International Earnings release: Q4 2025
Cryo-Cell International released its Q4 2025 earnings on February 27, 2026, summarizing the period's financial results.
Cryo-Cell downgraded to Hold from Buy at Maxim
Maxim analyst Allen Klee downgraded Cryo-Cell (CCEL) to Hold from Buy.
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells ...
Cryo-Cell International Quarterly report: Q3 2025
Cryo-Cell International has published its Q3 2025 quarterly earnings report on October 15, 2025.
Cryo-Cell International Earnings release: Q3 2025
Cryo-Cell International released its Q3 2025 earnings on October 15, 2025, summarizing the period's financial results.
Cryo-Cell International Proxy statement: Proxy filing
Cryo-Cell International filed a proxy statement on September 26, 2025, providing details for shareholder voting and corporate governance matters.
Cryo-Cell will not declare dividend in Q3
Cryo-Cell (CCEL) announced that the company will not declare a quarterly cash dividend for the third quarter of fiscal 2025. This decision reflects lower-than-expected profitability. Cryo-Cell may or ...
Cryo-Cell International, Inc. Provides Dividend Update
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”, “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced r...
Cryo-Cell International Quarterly report: Q2 2025
Cryo-Cell International has published its Q2 2025 quarterly earnings report on July 15, 2025.
Cryo-Cell International Earnings release: Q2 2025
Cryo-Cell International released its Q2 2025 earnings on July 15, 2025, summarizing the period's financial results.
Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announ...
Cryo-Cell International Quarterly report: Q1 2025
Cryo-Cell International has published its Q1 2025 quarterly earnings report on April 14, 2025.
Cryo-Cell International Earnings release: Q1 2025
Cryo-Cell International released its Q1 2025 earnings on April 14, 2025, summarizing the period's financial results.
Cryo-Cell price target lowered to $8.50 from $9 at Maxim
Maxim lowered the firm’s price target on Cryo-Cell (CCEL) to $8.50 from $9 and keeps a Buy rating on the shares. The company’s Q4 adjusted EBITDA miss was likely due…
Cryo-Cell reports FY24 EPS 5c vs ($1.14) last year
Reports FY24 revenue $32M vs $31.3M last year. David Portnoy, Cryo-Cell’s (CCEL) Chairman of the Board and Co-CEO remarked, “The Company’s 2024 fiscal results were impacted by continued investments re...